Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 4% primary Improvement Relative Risk Time to discharge 12% Gharbharan et al. NCT04342182 Conv. Plasma RCT LATE Is late treatment with convalescent plasma beneficial for COVID-19? RCT 86 patients in Netherlands Trial underpowered for serious outcomes Gharbharan et al., Nature Communications, doi:10.1038/s41467-021-23469-2 Favors conv. plasma Favors control
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
Gharbharan et al., Nature Communications, doi:10.1038/s41467-021-23469-2, NCT04342182 (history)
Gharbharan et al., Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe.., Nature Communications, doi:10.1038/s41467-021-23469-2, NCT04342182
May 2020   Source   PDF  
  All Studies   Meta
RCT 86 hospitalized patients, 43 treated with convalescent plasma, showing no significant differences with treatment. Authors conclude that the most likely explanation was already high antibody titers on the day of inclusion, and they recommend treating patients early. NCT04342182 (history).
risk of death, 3.8% lower, RR 0.96, p = 0.95, treatment 6 of 43 (14.0%), control 11 of 43 (25.6%), NNT 8.6, adjusted per study, odds ratio converted to relative risk, multivariable logistic regression, primary outcome.
time to discharge, 11.7% lower, relative time 0.88, p = 0.68, treatment 43, control 43, adjusted per study, multivariable Fine and Gray regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gharbharan et al., 27 May 2020, Randomized Controlled Trial, Netherlands, peer-reviewed, 32 authors, average treatment delay 10.0 days, trial NCT04342182 (history).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Abstract: ARTICLE OPEN 1234567890():,; Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection Arvind Gharbharan1,16, Carlijn C. E. Jordans1,16, Corine GeurtsvanKessel 1, Jan G. den Hollander2, Faiz Karim3, Femke P. N. Mollema4, Janneke E. Stalenhoef – Schukken 5, Anthonius Dofferhoff6, Inge Ludwig7, Adrianus Koster8, Robert-Jan Hassing9, Jeannet C. Bos10, Geert R. van Pottelberge11, Imro N. Vlasveld12, Heidi S. M. Ammerlaan13, Elena M. van Leeuwen – Segarceanu14, Jelle Miedema1, Menno van der Eerden1, Thijs J. Schrama 1, Grigorios Papageorgiou1, Peter te Boekhorst1, Francis H. Swaneveld15, Yvonne M. Mueller 1, Marco W. J. Schreurs1, Jeroen J. A. van Kampen1, Barry Rockx 1, Nisreen M. A. Okba 1, Peter D. Katsikis 1, Marion P. G. Koopmans 1, Bart L. Haagmans 1, Casper Rokx 1,16 ✉ & Bart J. A. Rijnders1,16 In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care to treatment with 300mL convalescent plasma containing high titers of neutralizing SARSCoV-2 antibodies, no overall clinical benefit was observed. Using a comprehensive translational approach, we unravel the virological and immunological responses following treatment to disentangle which COVID-19 patients may benefit and should be the focus of future studies. Convalescent plasma is safe, does not improve survival, has no effect on the disease course, nor does plasma enhance viral clearance in the respiratory tract, influence SARSCoV-2 antibody development or serum proinflammatory cytokines levels. Here, we show that the vast majority of patients already had potent neutralizing SARS-CoV-2 antibodies at hospital admission and with comparable titers to carefully selected plasma donors. This resulted in the decision to terminate the trial prematurely. Treatment with convalescent plasma should be studied early in the disease course or at least preceding autologous humoral response development. 1 Erasmus MC, University Medical Center, Rotterdam, The Netherlands. 2 Maasstad Hospital, Rotterdam, The Netherlands. 3 Groene Hart Hospital, Gouda, The Netherlands. 4 Haaglanden Medical Center, The Hague, The Netherlands. 5 OLVG Hospital, Amsterdam, The Netherlands. 6 Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. 7 Bernhoven Hospital, Uden, The Netherlands. 8 Viecuri Medical Center, Venlo, The Netherlands. 9 Rijnstate Hospital, Arnhem, The Netherlands. 10 Reinier de Graaf Gasthuis, Delft, The Netherlands. 11 ZorgSaam Hospital, Terneuzen, The Netherlands. 12 Martini Hospital, Groningen, The Netherlands. 13 Catharina Hospital, Eindhoven, The Netherlands. 14 Sint Antonius Hospital, Nieuwegein, The Netherlands. 15 Unit of Transfusion Medicine, Sanquin Blood Supply, Amsterdam, The Netherlands. 16These authors contributed equally: Arvind Gharbharan, Carlijn C.E. Jordans, Casper Rokx, Bart J.A. Rijnders. ✉email: NATURE COMMUNICATIONS | (2021)12:3189 | | 1 ARTICLE NATURE COMMUNICATIONS | S evere acute respiratory syndrome coronavirus 2 (SARSCoV-2), the cause of coronavirus disease 2019 (COVID-19), continues to put a tremendous strain on healthcare systems despite the advances that were made regarding the management of these patients. Anti-inflammatory therapy with dexamethasone significantly decreased mortality1...
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop